What is Nexpoint Real Estate's latest dividend and current dividend yield?

What is the revenue and EPS growth rate for Nexpoint Real Estate year over year?

What were the key takeaways from Nexpoint Real Estate's earnings call?

What does Nexpoint Real Estate do and what are its main business segments?

What factors drove the changes in Nexpoint Real Estate's revenue and profit?

What guidance did Nexpoint Real Estate's management provide for the next earnings period?

Did Nexpoint Real Estate beat or miss consensus estimates last quarter?

What is the market's earnings forecast for Nexpoint Real Estate next quarter?

- **Life Sciences Success**: Alewife project 2/3 leased with Lila Sciences, driving AI cluster and capital options.
- **Multifamily Recovery**: 2026 supply drop to 234K units, supporting revenue growth in constrained markets.
- **Balance Sheet Strength**: 0.93x D/E, $45M new notes at 7.875%, Series C preferred at 8% coupon.
- **Pipeline Growth**: $350M pipeline across multifamily, BTR, storage, and life sciences with low leverage enabling opportunistic buys.

**【CFO Financial Commentary】**
- Q3 2025 net income of $1.12 per diluted share, up from $0.74 in Q3 2024, driven by unrealized gains on preferred stock and warrants.
- Cash available for distribution: $0.53 per share (down 17% YoY) with dividend coverage of 1.06x.
- Book value per share increased 8% to $18.79, reflecting unrealized gains.
- Portfolio: $1.1B across 88 investments (47.3% multifamily, 33.9% life sciences) with 87.4% stabilized assets and 1.41x DSCR.
- Debt: $720.9M at 5.3% cost, with $45M new senior notes at 7.875% maturing in 2027.
- Series B preferred stock raise nearing $400M; planning $200M Series C at 8% coupon.

**【CIO Portfolio Discussion】**
- Multifamily supply peak in 2024 (695K units), expected to drop 49% YoY in 2026, supporting 2026 revenue growth.
- Life sciences focus on gateway markets: Alewife project leased 2/3 with Lila Sciences (245K sqft), creating AI cluster.
- Pipeline: $350M+ in investments ($120M multifamily, $75M BTR, $45M storage, $80M life sciences).
- Low leverage (0.93x D/E) and healthy dividend coverage enable opportunistic growth and stock buybacks.

**【Q&A Highlights】**
- **Life Sciences Sector**: NREF's 30% LTV life sciences loans in gateway markets (e.g., Boston's Alewife project) show resilience. Lila Sciences lease signals cluster formation and capital market optionality.
- **Multifamily Supply**: 2025 deliveries peak at 508K units, falling 49% YoY in 2026. New lease growth expected in 2026, especially in constrained markets like SF, NY, and Chicago. Sunbelt recovery lagging but inevitable.
- **Capital Deployment**: Preference for senior loans in stabilized assets; bridge loans under pressure due to 2021-2022 vintages, but 2026 outlook optimistic.

NexPoint Real Estate Finance, Inc. (NREF) Q3 2025 Earnings Call Transcript

- **Financial Resilience**: 35% YoY net income growth, despite lower EAD/CAD, supported by 8% life science lease yield.
- **Portfolio Diversification**: 49.5% multifamily, 32.7% life science, balanced risk with 1.14x D/E ratio.
- **Pipeline Momentum**: $235M pipeline to boost CAD, targeting high single-digit growth.
- **Strategic Wins**: Alewife project lease underscores ability to capitalize on niche opportunities.
- **Credit Strength**: 58.5% LTV, 1.44x DSCR, lowest leverage in CMREIT sector.

**【CFO Financial Commentary】**
- **Net Income Growth**: $0.54 per share, up 35% year-over-year, driven by $4.6 million increase in interest income to $22.8 million.
- **Earnings Metrics**: Earnings available for distribution ($0.43) and cash available for distribution ($0.46) down 37% and 31% YoY, with dividend coverage at 0.92x.
- **Balance Sheet**: Book value per share increased 1% to $17.40, supported by $39.5 million life science investment and $15.3 million CMBS IO purchase.
- **Portfolio Overview**: $1.1 billion across 86 investments, 74% stabilized collateral with 1.44x DSCR. Debt-to-equity ratio of 1.14x at 5.9% cost.
- **Q3 Guidance**: Midpoint of $0.42 for EAD and $0.50 for CAD, reflecting cautious optimism.

**【CIO Portfolio Discussion】**
- **Residential Sector**: 400,000 units delivered in 12 months, 94.6% occupancy rate, with rental rate inflection expected post-2025 supply slowdown.
- **Life Science Highlight**: 245,000 sq. ft. lease with AI biologics company at 8% debt yield, part of $235 million pipeline targeting CAD growth.
- **Storage Market**: Flat to negative NOI growth, but occupancy improving in major markets like Massachusetts and Texas.
- **Credit Profile**: Portfolio with 58.5% LTV and strong liquidity, enabling selective growth opportunities.

**【Q&A Highlights】**
- **B-Piece Portfolio Stability**: Despite minor delinquencies, 2018-2025 vintages show resilience, with 2021 floating-rate loans under watch.
- **Life Science Lease Details**: 2/3 occupancy post-lease, 2.5-year duration, with potential refinancing via back-leverage.
- **Seniors Housing Interest**: Positive outlook on build-to-rent projects, with Welltower outperformance signaling sector recovery.

NexPoint Real Estate Finance (NREF)-31 Jul 25-2025 Q2 Earnings call transcript

- **Financial Recovery**: Q1 net income turned positive ($0.70 vs. $0.83 loss), driven by 15% YoY interest income growth.
- **Life Science Breakthrough**: 2/3 of Alewife project leased with 11% debt yield; reshoring trends boost manufacturing asset demand.
- **Residential Strength**: 138,000 Q1 units absorbed; 40% portfolio seeing rental growth, signaling bottoming market.
- **Self-Storage Growth**: 4 new projects targeting 18.5% returns; $75M+ equity to deploy in 2025.
- **Credit Stability**: 58.7% LTV, 1.46x DSCR; minimal impact from macro uncertainty.

**【Paul Richards - Financial Highlights】**
- **Q1 2025 Net Income**: $0.70 per diluted share (vs. $0.83 loss in Q1 2024), driven by $23.6M increase in interest income due to higher rates.
- **Cash Available for Distribution**: $0.45 per share (vs. $0.60 in Q1 2024), with dividend coverage at 0.9x.
- **Book Value**: $17.22 per share (+1.47% QoQ), boosted by unrealized gains on preferred stock.
- **Debt Metrics**: $831.5M total debt (52.1% short-term), weighted average cost of 6%, debt-to-equity ratio of 1.33x.
- **Q2 Guidance**: Earnings available for distribution of $0.43-$0.48 per share, cash available for distribution of $0.43-$0.53 per share.

**【Matthew McGraner - Portfolio & Market Insights】**
- **Life Science Sector**: 2/3 of Alewife project leased with 11% debt yield; bullish on CGMP/manufacturing due to reshoring trends (e.g., Apple, Roche, Intel).
- **Residential Real Estate**: 138,000 units absorbed Q1 (record pace), 40% of portfolio seeing positive lease growth; expect rental growth and transaction volume recovery.
- **Self-Storage Developments**: 4 projects (8.1%-8.5% yield on cost), targeting 18.5% returns post-leverage; $75M+ equity to deploy in 2025.
- **Credit Performance**: Low credit risk (58.7% LTV, 1.46x DSCR); proactive reserve for private preferred equity ($40M remaining to fund).

**【Q&A Key Takeaways】**
- **Credit Loss Provision**: 50-50 split between CECL reserve and private preferred equity; no material impact on portfolio stability.
- **Life Science Momentum**: Alewife project nearing 2/3 lease completion; broader sector delays expected to resolve in Q2-Q3.
- **Future Investment Focus**: CMBS B-P pieces (250-350bp spread) and multifamily pre-leasing deals; $150M+ pipeline for short-term stretch seniors.

NexPoint Real Estate Finance (NREF)-1 May 25-2025 Q1 Earnings call transcript

- **Strong Financial Resilience**: 67% YoY net income growth with 18% cash available for distribution expansion.
- **Balanced Portfolio Growth**: 49.7% multifamily exposure, 31% life sciences allocation, and 1.39x debt-to-equity ratio.
- **High-Return Opportunities**: 8-9% Freddie K loan yields and $300M life sciences pipeline targeting reshoring trends.
- **Credit Stability**: 1.32x DSCR, 59.2% LTV, and minimal delinquencies in CMBS portfolio.


**【CFO Financial Highlights】**
- Q4 2024 Net Income: $0.43 per diluted share (vs. $0.73 in Q4 2023), driven by unrealized losses on common stock investments.
- Interest Income: $32.3M (15% YoY increase) due to higher rates; Interest Expense: $2.5M decline from deleveraging.
- Cash Available for Distribution: $0.47 per share (0.94x dividend coverage) vs. $0.51 in Q4 2023.
- Book Value: $16.97 per share (4bps QoQ increase) from preferred stock gains.
- Full Year 2024 Net Income: $1.02 per share (67% YoY increase) with 18% growth in cash available for distribution.

**【CEO Portfolio Overview】**
- Portfolio Composition: 83 investments totaling $1.2B, with 49.7% in multifamily, 31% in life sciences, and 15.5% in single-family rental.
- Credit Metrics: 76.5% stabilized assets, 59.2% LTV, 1.32x DSCR, and $799M debt (50.2% short-term, 6% WAC).
- 2025 Growth Drivers: 
  - Multifamily: 37K Q4 units (lowest since 2011), expecting 2H lease growth.
  - Self-Storage: Flat to positive NOI, $75M pipeline of construction financings.
  - Life Sciences: $300M pipeline in advanced manufacturing, GMP facilities, and reshoring trends.

**【Q&A Key Takeaways】**
- **Freddie K Deals**: 5-year fixed-rate loans ($30-50M) with 8-9% yields, targeting low-teens returns with accretive leverage.
- **Life Sciences Performance**: Cambridge project (395K sqft) 25% LTV, 30+ basis points stabilized yield; bids received at SOFR+900 basis points.
- **Credit Quality**: Minimal delinquencies (2/8 B-piece loans), with refinancing activity expected in Q2.
- **Capital Allocation**: Series B preferred equity ($38.8M raised) and A-note warehouses to fund $75M+ pipeline.


NREF

NREF fundamentals

Earnings Call

You can ask Aime